These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2523194)

  • 1. Adverse effects related to thionamide drugs and their dose regimen.
    Werner MC; Romaldini JH; Bromberg N; Werner RS; Farah CS
    Am J Med Sci; 1989 Apr; 297(4):216-9. PubMed ID: 2523194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
    Kubota S
    Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
    Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism.
    Momotani N; Noh JY; Ishikawa N; Ito K
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3633-6. PubMed ID: 9360518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease.
    Tsuboi K; Ueshiba H; Shimojo M; Ishikawa M; Watanabe N; Nagasawa K; Yuasa R; Yoshino G
    Endocr J; 2007 Feb; 54(1):39-43. PubMed ID: 17053291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
    Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
    J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The propylthiouracil dilemma.
    Glinoer D; Cooper DS
    Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):402-7. PubMed ID: 22820213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China.
    Yang J; Li LF; Xu Q; Zhang J; Weng WW; Zhu YJ; Dong MJ
    Thyroid; 2015 Mar; 25(3):278-83. PubMed ID: 25384184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.
    Okamura K; Ikenoue H; Shiroozu A; Sato K; Yoshinari M; Fujishima M
    J Clin Endocrinol Metab; 1987 Oct; 65(4):719-23. PubMed ID: 3654917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
    J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicities associated with 1-month treatment with propylthiouracil (PTU) and methimazole (MMI) in male rats.
    Nambiar PR; Palanisamy GS; Okerberg C; Wolford A; Walters K; Buckbinder L; Reagan WJ
    Toxicol Pathol; 2014 Aug; 42(6):970-83. PubMed ID: 24067673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.
    Wang MT; Lee WJ; Huang TY; Chu CL; Hsieh CH
    Br J Clin Pharmacol; 2014 Sep; 78(3):619-29. PubMed ID: 25279406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of antithyroid drugs in pregnancy: update and therapy implications.
    Francis T; Francis N; Lazarus JH; Okosieme OE
    Expert Opin Drug Saf; 2020 May; 19(5):565-576. PubMed ID: 32223355
    [No Abstract]   [Full Text] [Related]  

  • 19. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose.
    Cooper DS; Goldminz D; Levin AA; Ladenson PW; Daniels GH; Molitch ME; Ridgway EC
    Ann Intern Med; 1983 Jan; 98(1):26-9. PubMed ID: 6687345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Ohye H; Suzuki M; Yoshihara A; Iwaku K; Sugino K; Ito K
    Thyroid; 2014 May; 24(5):796-801. PubMed ID: 24341564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.